[1]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809-811,858.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
　(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(9):809-811,858.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
点击复制

贝派地酸降脂疗效及安全性的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年9期
页码:
809-811,858
栏目:
综述
出版日期:
2021-09-25

文章信息/Info

Title:
YUAN Ronghui1,BAI Chunlin2
文章编号:
202103066
作者:
袁荣辉1 白春林 2
(1.山西医科大学,山西 太原 030001;2.山西医科大学第二医院心内科,山西 太原 030001)
Author(s):
(1.Shanxi Medical University; Taiyuan 030001; Shanxi; China; 2. Cardiology Department;  The Second Hospital of Shanxi Medical University; Taiyuan 030001; Shanxi; China)
关键词:
贝派地酸; 血脂异常; 低密度脂蛋白胆固醇
Keywords:
Bempedoic acid;  Dyslipidemia; Low-density lipoprotein cholesterol
DOI:
10.16806/j.cnki.issn.1004-3934.2021.09.000
摘要:
血脂异常通常指血清胆固醇、甘油三酯和低密度脂蛋白胆固醇（LDL-C）水平升高。高密度脂蛋白胆固醇水平降低，可导致冠心病等动脉粥样硬化性心血管疾病，而LDL-C升高是导致动脉粥样硬化性心血管疾病发病的关键因素。目前国内外调脂首选他汀类药物，然而有大量研究显示高强度他汀类药物治疗会大幅度升高肌病风险，而且不能有效降低LDL-C水平。贝派地酸（ETC-1002）作为一种能降低LDL-C水平的新型口服降脂药物，于2020年2月在美国和欧洲被批准上市，相比他汀类药物，其肌肉相关副作用大大减低。现从贝派地酸降脂作用的基础研究和有效性及安全性的最新证据做一综述。
Abstract:
Dyslipidemia usually refers to elevated levels of serum cholesterol, triglycerides,low-density lipoprotein cholesterol(LDL-C) and reduced levels of high-density lipoprotein cholesterol,which can lead to atherosclerotic cardiovascular disease such as coronary heart disease,and elevated LDL-C is a key factor in the development of atherosclerotic cardiovascular disease. Currently, statins are the first choice for lipid regulation in China and abroad,however, studies have shown that high-intensity statin therapy substantially increases the risk of myopathy and fails to effectively reduce LDL-C levels. Bempedoic acid(ETC-1002),a novel oral lipid-lowering drug that reduces LDL-C levels,was approved for marketing in the United States and Europe in February 2020 with substantially reduced muscle-related side effects compared with statins. This article reviews the basic research and the latest evidence of the efficacy and safety of the lipid-lowering effect of bempedoic acid

参考文献/References:

[1] Wójcik C. Emerging lipid lowering agents targeting LDL cholesterol[J]. Postgrad Med,2020,132(5):433-440.

[2] Collins R,Reith C,Emberson J,et al. Interpretation of the evidence for the efficacy and safety of statin therapy [J]. Lancet,2016,388(10059):2532-2561.

[3] Ference BA,Yoo W,Alesh I,et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease:a Mendelian randomization analysis [J]. J Am Coll Cardiol,2012,60(25):2631-2639.

[4] Mihaylova B,Emberson J,Blackwell L,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials [J]. Lancet,2012,380(9841):581-590.

[5] Ji Y,Bai C. Research progress of hypertriglyceridemia and coronary heart disease [J]. Heart Mind,2018,2(2):40-44.

[6] Baigent C,Blackwell L,Emberson J,et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials [J]. Lancet,2010,376(9753):1670-1681.

[7] Nguyen D,Du N,Sulaica EM, et al. Bempedoic acid:a new drug for an old problem[J]. Ann Pharmacother,2021,55(2):246-251.

[8] Saeed A,Ballantyne CM. Bempedoic acid(ETC-1002):a current review[J]. Cardiol Clin,2018,36(2):257-264.

[9] Pinkosky SL,Filippov S,Srivastava RA,et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002,a novel small molecule regulator of lipid and carbohydrate metabolism [J]. J Lipid Res,2013,54(1):134-151.

[10] Samsoondar JP,Burke AC,Sutherland BG,et al. Prevention of diet-induced metabolic dysregulation,inflammation,and atherosclerosis in Ldlr(-/-) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid [J]. Arterioscler T hromb V asc B iol,2017,37(4):647-656.

[11] Burke AC,Telford DE,Sutherland BG,et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient(LDLR +/- and LDLR -/-) Yucatan miniature pigs[J]. Arterioscler T hromb V asc B iol,2018,38(5):1178-1190.

[12] Ballantyne CM,Banach M,Mancini GBJ,et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized,placebo-controlled study [J]. Atherosclerosis,2018,277:195-203.

[13] Goldberg AC,Leiter LA,Stroes ESG,et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease:The CLEAR Wisdom Randomized Clinical Trial [J]. JAMA,2019,322(18):1780-1788.

[14] Pinkosky SL,Newton RS,Day EA,et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis [J]. Nat Commun,2016,7:13457.

[15] Ray KK,Bays HE,Catapano AL,et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med,2019,380(11):1022-1032.

[16] Laufs U,Banach M,Mancini GBJ,et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance [J]. J Am Heart Assoc,2019,8(7):e011662.

[17] Asbeutah AAA,Asbeutah SA,Abu-Assi MA. A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with bempedoic acid [J]. Am J C ardiol,2020,132:166-168.

[18] di Minno A,Lupoli R,Calcaterra I,et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia:systematic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc,2020,9(15):e016262.

[19] Khan MU,Khan MZ,Munir MB, et al. Meta-analysis of the safety and efficacy of bempedoic acid[J]. Am J Cardiol,2020,131:130-132.

相似文献/References:

[1]杨晓倩 秦莉 张艺文 童兰 汪汉.糖皮质激素与心血管疾病[J].心血管病学进展,2020,(4):404.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.019]
　YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Glucocorticoid and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):404.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.019]
[2]孟凡华 付真彦.一种新型的治疗血脂异常的干扰RNA药物Inclisiran[J].心血管病学进展,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
　MENG Fanhua,FU Zhenyan.Inclisiran, A New Small Interfering RNA Drug for the Treatment of Dyslipidemia[J].Advances in Cardiovascular Diseases,2021,(9):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
[3]张嘉原 张莉.果糖代谢与血脂异常的研究进展[J].心血管病学进展,2022,(12):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]
　ZHANG Jiayuan ZHANG Li.Fructose Metabolism and DyslipidemiaA Systematic Review[J].Advances in Cardiovascular Diseases,2022,(9):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]

更新日期/Last Update: 2021-10-21